Cargando…
Imaging of Oligometastatic Disease
SIMPLE SUMMARY: The imaging of oligometastatic disease (OMD) is challenging as it requires precise loco-regional staging and whole-body assessment. The combination of imaging modalities is often required. The more accurate imaging tool will be selected according to tumor type, the timing with regard...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946296/ https://www.ncbi.nlm.nih.gov/pubmed/35326586 http://dx.doi.org/10.3390/cancers14061427 |
_version_ | 1784674162379325440 |
---|---|
author | Vietti Violi, Naik Hajri, Rami Haefliger, Laura Nicod-Lalonde, Marie Villard, Nicolas Dromain, Clarisse |
author_facet | Vietti Violi, Naik Hajri, Rami Haefliger, Laura Nicod-Lalonde, Marie Villard, Nicolas Dromain, Clarisse |
author_sort | Vietti Violi, Naik |
collection | PubMed |
description | SIMPLE SUMMARY: The imaging of oligometastatic disease (OMD) is challenging as it requires precise loco-regional staging and whole-body assessment. The combination of imaging modalities is often required. The more accurate imaging tool will be selected according to tumor type, the timing with regard to measurement and treatment, metastatic location, and the patient’s individual risk for metastasis. The most commonly used modalities are contrast-enhanced computed tomography (CT), magnetic resonance imaging and metabolic and receptor-specific imaging, particularly, (18)F-fluorodesoxyglucose positron emission tomography/CT, used alone or in combination. ABSTRACT: Oligometastatic disease (OMD) is an emerging state of disease with limited metastatic tumor burden. It should be distinguished from polymetastatic disease due the potential curative therapeutic options of OMD. Imaging plays a pivotal role in the diagnosis and follow-up of patients with OMD. The imaging tools needed in the case of OMD will differ according to different parameters, which include primary tumor type, timing between measurement and treatment, potential metastatic location and the patient’s individual risk for metastasis. In this article, OMD is defined and the use of different imaging modalities in several oncologic situations are described in order to better understand OMD and its specific implication for radiologists. |
format | Online Article Text |
id | pubmed-8946296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89462962022-03-25 Imaging of Oligometastatic Disease Vietti Violi, Naik Hajri, Rami Haefliger, Laura Nicod-Lalonde, Marie Villard, Nicolas Dromain, Clarisse Cancers (Basel) Review SIMPLE SUMMARY: The imaging of oligometastatic disease (OMD) is challenging as it requires precise loco-regional staging and whole-body assessment. The combination of imaging modalities is often required. The more accurate imaging tool will be selected according to tumor type, the timing with regard to measurement and treatment, metastatic location, and the patient’s individual risk for metastasis. The most commonly used modalities are contrast-enhanced computed tomography (CT), magnetic resonance imaging and metabolic and receptor-specific imaging, particularly, (18)F-fluorodesoxyglucose positron emission tomography/CT, used alone or in combination. ABSTRACT: Oligometastatic disease (OMD) is an emerging state of disease with limited metastatic tumor burden. It should be distinguished from polymetastatic disease due the potential curative therapeutic options of OMD. Imaging plays a pivotal role in the diagnosis and follow-up of patients with OMD. The imaging tools needed in the case of OMD will differ according to different parameters, which include primary tumor type, timing between measurement and treatment, potential metastatic location and the patient’s individual risk for metastasis. In this article, OMD is defined and the use of different imaging modalities in several oncologic situations are described in order to better understand OMD and its specific implication for radiologists. MDPI 2022-03-10 /pmc/articles/PMC8946296/ /pubmed/35326586 http://dx.doi.org/10.3390/cancers14061427 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vietti Violi, Naik Hajri, Rami Haefliger, Laura Nicod-Lalonde, Marie Villard, Nicolas Dromain, Clarisse Imaging of Oligometastatic Disease |
title | Imaging of Oligometastatic Disease |
title_full | Imaging of Oligometastatic Disease |
title_fullStr | Imaging of Oligometastatic Disease |
title_full_unstemmed | Imaging of Oligometastatic Disease |
title_short | Imaging of Oligometastatic Disease |
title_sort | imaging of oligometastatic disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946296/ https://www.ncbi.nlm.nih.gov/pubmed/35326586 http://dx.doi.org/10.3390/cancers14061427 |
work_keys_str_mv | AT viettiviolinaik imagingofoligometastaticdisease AT hajrirami imagingofoligometastaticdisease AT haefligerlaura imagingofoligometastaticdisease AT nicodlalondemarie imagingofoligometastaticdisease AT villardnicolas imagingofoligometastaticdisease AT dromainclarisse imagingofoligometastaticdisease |